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(mean of 16.5kg). The average screening time was 33min 
(SD ± 22.7).
Echocardiography was normal in 32 (72.7%) of cases. 
Abnormalities on echocardiography were: Epstein’s with peri-
membranous VSD, a secundum ASD, hypertrophic cardio-
myopathy, tricuspid atresia with right ventricular outflow tract 
conduit and percutaneous Melody valve, tetralogy of Fallot, 
double outlet right ventricle (DORV), hypoplastic left heart 
(HLH) syndrome and premature closure of the ductus 
arteriosus.
Diagnosis at invasive electrophysiology study was atrioventri-
cular reentry tachycardia (AVRT) in 26 (50.9%), ectopic atrial 
tachycardia (EAT) in 7 (13.7%), intraatrial re-entry tachycardia 
(IART) in 5 (9.8%), atrioventricular nodal reentry tachycardia 
in 11 (21.6%) and ventricular tachycardia (VT) in 2 (3.9%) 
patients. The 2 cases of VT were left ventricular outflow tract 
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INTRODUCTION
The diagnosis and treatment of arrhythmias in children remain 
challenging. Diagnosis is difficult due to the fact that infants 
and young children cannot communicate symptoms and 
often present with haemodynamic compromise. Antiarrhythmic 
drugs, namely beta blockers, class Ic and class III drugs, were the 
only treatment available for many years. Alternatives to medical 
treatment include no treatment, surgical ablation and radio-
frequency catheter ablation.(1) Surgical ablation (including the 
Maze procedure), a precursor to RF ablation, is much more 
invasive and more commonly performed in complex arrhyth-
mias in older patients with concurrent surgical intervention. 
RF ablation was first introduced in paediatric patients in 
1989. However, various questions remain regarding the safety 
and efficacy. 
METHODS
A retrospective analysis of patient records, 12 years and 
younger, at Leuven University Hospital, from January 2011 - 
July 2015 was performed. Patients’ demographics including 
age, sex and weight; echocardiographic findings, indication 
for RFCA, screening time, outcomes and complications were 
recorded. 
RESULTS
From January 2011 - July 2015 a total of 51 ablations were 
performed in 44 patients. All cases were performed under 
general anaesthesia. The mean age was 7 years (with a range 
from 3 weeks - 12 years); 11 patients (21.5%) were younger 
than the age of 2 years. Weights ranged from 3.4 - 56kg 
Background: Diagnosis and treatment of paediatric 
arrhythmias remain challenging.  Antiarrhythmic drugs - 
beta-blockers, class Ic and class III drugs, were the only 
treatment available for many years. Radiofrequency 
catheter ablation (RFCA) was introduced for adult 
patients in 1981 and has been used for children since 
1989. Questions remain regarding the effi cacy and 
safety in paediatrics.
Method: A retrospective analysis of patient records, 12 
years and younger, at Leuven University Hospital, from 
January 2011 - July 2015 was performed.
Results: From January 2011 - July 2015, 51 ablations 
were performed in 44 patients ≤12 years of age. Mean 
age was 7 years (range 3 weeks - 12 years), 11 (21.5%) 
≤2 years; mean weight 16.5kg (range 3.4 - 56kg); average 
screening time 33.5min (SD ± 22.7). Echocardiography 
was normal in 32 (72.7%) of patients. All cases were 
done under general anaesthesia. Diagnosis at electro-
physiological study: Atrioventricular reentry tachy-
cardia in 26 (50.9%), atrial ectopic tachycardia in 7 
(13.7%), intra-atrial reentry tachycardia in 5 (9.8%), 
atrioventricular nodal reentry tachycardia in 11 (21.6%) 
and ventricular tachycardia in 2 (3.9%). RFCA was 
successful in 44 (86.3%) with recurrence rate of 13.7%. 
No signifi cant complications were noted. 
Conclusion: RFCA can be performed safely and 
effectively in even the very young. Recurrence and com-
plication rates are similar to those reported in adults. 
RFCA should be the treatment of choice in selected 













tachycardia (LVOT VT) in a patient with a normal heart, and 
right ventricular outflow tract tachycardia (RVOT VT) originating 
from under the Melody valve in the patient with post operative 
tricuspid atresia.
The acute success rate was 86.3% (44 ablations), with a 
recurrence rate of 13.7%. Recurrence occurred in a 5-year-old 
with Epstein’s anomaly and Wolf Parkinson White syndrome 
(WPW), a 6-year-old with 2 accessory pathways (posteroseptal 
and a concealed right lateral accessory pathway [AP]), a 3-year-
old with a right anterolateral and left lateral AP, a 2-month-old 
with HLH syndrome and IART, a 4-month-old with right atrial 
isomerism, DORV and EAT, and a 10-month-old with a 
structurally normal heart and EAT. In one case, a 3-year-old 
with a concealed anteroseptal AP, ablation was abandoned 
due to the high risk of AV block. No significant complications 
were found.
DISCUSSION
In recent years RFCA has increasingly been used as curative 
treatment for a variety of arrhythmias in children and 
adolescents. In patients, over 12 - 15kg in experienced paediatric 
electrophysiology centres the success rate is high and the risk 
of severe complications is low, comparable to data from 
adult studies.(2-4) It remains an invasive procedure though, and 
before deciding whether to proceed to RF ablation a thorough 
understanding is needed of the tachycardia substrates, the 
natural history and outcomes of RF ablation. 
Tachycardia substrates in children
Supraventricular tachycardia (SVT) are by far the most prevalent 
arrhythmias in children without structural congenital heart 
disease (CHD). In all ages, AVRT due to an AP is the most 
common with a prevalence of 0.1 - 0.15%. In infants, AVRT 
accounts for 80% of cases, EAT for 15% and AVNRT for 5%. 
Permanent junctional reciprocating tachycardia (PJRT) and 
congenital junctional ectopic tachycardia (JET) are less 
commonly encountered but, both may be incessant and lead 
to ventricular dysfunction. JET is also uncommonly encountered 
in neonates with CHD undergoing surgery. Atrial flutter is 
rarely seen outside the neonatal period. With increasing age, 
AVNRT becomes more common, approaching adult incidence. 
In the age group 1 - 5 years AVRT remains most common at 
65%, AVNRT in 25% and EAT in 10% of cases.(5) Atrial fibril-
lation (AF) is extremely rare, occurs most typically in patients 
with manifest pre-excitation and initiation might be due to 
degeneration from AVRT.(6)
Sustained VT is rare in children with an estimated incidence of 
between 0.2 and 0.8 per 10 000 children.(7) 
In patients with CHD the arrhythmia may be associated with 
the underlying abnormality or with surgical intervention 
which provides a highly favourable substrate for re-entrant 
arrhythmias.(8)
Clinical presentation and natural history
There are very few natural history studies concerning tachy-
cardia in childhood, most looking at AVRT. It is estimated that 
most patients with AVRT in infancy will have no recurrences 
once medication is stopped after the age of 1 year with 
tachycardia recurring in approximately 30% at an average 
age of 7 - 8 years.(9) The conduction properties of both the AP 
and AV node change as the child matures with loss of 
anterograde conduction over the AP in as many as 40% of 
patients, making SVT non-inducible. However, if tachycardia 
and WPW coexist beyond 5 years of age it is likely to to still 
be present after a decade in 75% of patients. On occasion, 
with prolonged periods of tachycardia, haemodynamic collapse 
might result. In most cases, though, recurrences are well 
tolerated. It has been reported that up to 10% of patients 
with WPW and AVRT may present with life threatening 
symptoms.(9) Prolonged tachy-cardia may lead to tachycardia-
induced cardiomyopathy and needs to be distinguished from 
other causes of cardiomyopathy as it is curable. Sudden cardiac 
death (SCD) may occur due to rapid conduction over the AP 
during atrial fibrillation resulting in ventricular fibrillation (VF). 
The risk for SCD is estimated to be up to 1.3 - 1.6% with the 
highest incidence in the first 2 decades of life.(10) Risk stratifica-
tion for a life threatening-arrhythmia on history alone is 
problematic with red flags being younger age (<30 years), male 
gender, history of AF, prior syncope, associated CHD and 
familial WPW. Noninvasive risk stratification includes measuring 
the Shortest Pre-Excited R-R Interval (SPERRI) on ECG during 
AF, with an SPERRI of 220 - 250ms being a risk for SCD, and 
proving the disappearance of preexcitation at physiological 
heart rates (e.g. Holter or exercise stress test). Interobserver 
reliability of loss of delta wave remains problematic as pre-
excitation may be masked by rapid AV conduction. 
With VT the outcome is favourable, especially in infants 
presenting with RVOT VT. In a large retrospective, multicentre 
analysis of idiopathic childhood VT, only nine of 98 patients 
required RFCA.(6) About half of patients with sustained VT have 
no structural heart disease and are divided between neonatal 
idiopathic left and idiopathic right VTs, with the majority (53%) 
originating from the right ventricle. Sustained VT disappears in 
half of the cases with no underlying CHD, with the only 
mortality having been reported in patients with underlying 
CHD. Thus, sustained VT in children with no underlying CHD 
is rare and carries a good prognosis.(7)
Diagnostic electrophysiology study (EPS)
In most cases, the mechanism and hence treatment of 
arrhythmias, can be largely established by history taking,(12) lead 
electrocardiogram (ECG) and using non-invasive techniques 
like a bipolar oesophageal electrode to perform an EPS. Atrial 
overdrive pacing can also be performed via an oesophageal 
electrode and is successful in virtually all cases of SVT and up 
to 73% of cases of IART/ atrial flutter.(11) The indications for 
EPS and ablation are almost similar in children with SVT with 
the exception of risk stratification for SCD in children with 
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asymptomatic preexcitation. Due to the limitations of non-
invasive risk stratification up to 84% of surveyed paediatric 
electrophysiologists use some form of EPS in asymptomatic 
children with WPW and 77% would perform RFCA when the 
SPERRI is <240ms. When the anterograde characteristics of 
the AP is not clear on noninvasive testing invasive EPS should 
be considered. Risk factors for VF and SCD are SPERRI 
≤220ms, APERP (effective refractory period) of <240ms, 
multiple APs and possibly septal bypass tracks.(9) 
EPS is usually performed in conjunction with RFCA once it has 
been decided to eliminate a documented VT.(7) 
Radiofrequency catheter ablation
The indications for RFCA were reported by 2 PACES/HRS 
expert consensus documents and are documented in Table I(8) 
and in Table II the indications for RFCA in children with 
idiopathic ventricular arrhythmias.(7) In addition to these recom-
mendations, RFCA may also be considered in patients with 
asymptomatic preexcitation and CHD before surgery that 
might limit access for future catheter based procedures.(10) 
The success and complication rates reported by the Paediatric 
Radiofrequency Catheter Ablation Registry and the Paediatric 
Electrophysiology Society (PACES) are similar to those in 
adults. The acute overall success rate is very high at around 
95% for AVRT or AVNRT, with higher success rates for left 
sided AP and particularly left free-wall pathways (97.8%) than 
right free-wall pathways (90.8%).(2,4,12)
Complications reported included AV block, bleeding, stroke, 
infection, damage to the cardiac valves, coronary artery spasm 
and radiation exposure. With diagnostic EPS the most common 
complication was haematoma and with RFCA, AV nodal block 
(1.2%) limited to ablation of septal pathways (3.0%) and 
AVNRT (2.1%). Techniques to avoid AV block include intuba-
tion and apnoea during ablation, pacing in the coronary sinus to 
monitor AV conduction, using lower temperatures and power 
settings, ablating during tachycardia and mapping the position of 
the His-bundle prior to application.(13)
The number of APs present may also influence the safety and 
efficacy of RFCA.(14) Those with multiple pathways, compared 
to patients with single AP, had a higher incidence of anti-
dromic tachycardia, a shorter anterograde AP effective 
refractory period, longer fluoroscopy time and a larger number 
of unsuccessful attempts. Success rate (92% vs. 93%) and 
recurrence rate (1.7% vs. 2.1%) were, however, similar. Other 
complications, including coronary artery injury during 
endocardial ablation near the AV groove, occur much less 
frequently.(15)
In a large retrospective, multicentre analysis of idiopathic 
childhood VT only 9 of 98 patients required RFCA, with a 
success rate of 78%.(13)
In infants less <15kg RFCA is generally deferred unless a specific 
indication exist, like refractory or life threatening arrhythmias 
with associated ventricular dysfunction. Procedure modifications 
also need to be made for example using 4F diagnostic catheter 
and 5F ablation catheter, or a single catheter technique. In a 
retrospective analysis comparing RFCA in infants <18 months 
to older children no difference was found, either for success 
rate, or incidence of major complications.(16) Secondary analysis 
of patients weighing <15kg, including those older than 18 
months, showed an increase in major, but not overall, com-
plication rate.
D
TABLE I: Indications for radiofrequency catheter ablation in 
paediatric patients.
Class I: There is consistent agreement and/or supportive data that catheter ablation is 
likely to be medically beneficial or helpful for the patient.
Class II: There is a divergence of opinion regarding the benefit or medical necessity of 
catheter ablation. II A: The majority of opinions/data are in favour of the procedure. 
II B: There is clear divergence of opinion regarding the need for the procedure.
Class III: There is agreement that catheter ablation is not medically indicated and/or 
the risk of the procedure may be greater than benefit for the patient.
AP = accessory pathway, AVN = atrioventricular node, ECG = electrocardiogram,  
IART = intra-atrial reentrant tachycardia, SVT = supraventricular tachycardia, 
VT = ventricular tachycardia, WPW = Wolff-Parkinson-White, 
AA = antiarrhytmic therapy.
Adapted from Brugada J, et al. Pharmacological and non-pharmacological therapy for 
arrhythmias in the paediatric population: EHRA and AEPC-Arrhythmia working group 
joint consensus statement. Europace 2013;15:1337-1382 and Page RL, et al. 2015 






WPW syndrome following an episode of aborted sudden 
cardiac death.
The presence of WPW syndrome associated with syncope 
when there is a short R-R interval during atrial fi brillation 
(preexcited R-R interval 250ms) or the anterograde effective 
refractory period of the AP measured during programmed 
electrical stimulation is <250ms.
Chronic or recurrent SVT associated with ventricular 
dysfunction.
Recurrent VT that is associated with haemodynamic 
compromise and is amenable to catheter ablation.
WPW syndrome and recurrent and/or symptomatic SVT and 
age >5 years.
WPW syndrome and palpitations with inducible sustained SVT 
during EPS, age >5 years.
SVT, age >5 years, chronic AA therapy has been effective in 
control of the arrhythmia.
SVT, age <5 years (including infants), when AA medication, 
including classes I and III are not effective or associated with 
intolerable side effects.
WPW syndrome and recurrent and/or symptomatic SVT and 
age <5 years.
Single or infrequent SVT (no pre-excitation), age >5 years.
Asymptomatic preexcitation, age >5 years, no recognised 
tachycardia, risks and benefi ts of procedure and arrhythmia 
clearly explained.
Asymptomatic preexcitation, age <5 years.













Mapping and ablation systems
Conventional mapping using multipolar catheters placed at 
specific locations under fluoroscopy recording activation 
sequence at baseline and in response to various pacing 
protocols remain the gold standard for most children with 
structurally normal hearts. However, patients with congenital 
heart disease are often encountered in paediatric electro-
physiology. Conventional mapping may be difficult due to 
inconsistent anatomical and surgical landmarks coupled with 
areas of low-voltage myocardium and scarring, leading to long 
procedure and fluoroscopy times. Three dimensional elctro-
anatomical mapping significantly facilitates these procedures.
The EnSite NavX system (St Jude Medical, St Paul, Minnesota, 
USA) uses standard electrophysiological catheters to sense 
the electrical signals transmitted between 3 pairs of electrode 
patches. Three dimensional reconstruction can thus be created 
and areas of interest annotated. 
By serial acquisition of endocardial points, a 3 dimensional 
reconstruction can be created using elepctroanatomical 
mapping (CARTO, Biosense Webster, Diamond Bar, California, 
USA). The catheter tip can be located, in 3 dimensions, within 
the heart to within 1mm using special catheters and a location 
magnet. Using a stable reference catheter, serial cardiac 
activation is acquired, colour coded and superimposed on the 
anatomical map. Surgical and anatomical structures can be 
added as may electrophysiologically important points like 
double potentials or areas of scar. Pre-procedure MRI/CT 
may be useful in patients with CHD as the images can be 
superimposed onto the anatomical map (CARTO-UNIVU) 
leading to better definition of anatomy and reducing radiation 
dose. The long-term outcome of ablation in patients with 
congenital heart disease has been shown to be improved by 
the use of electroanatomical mapping.(17) Limiting factors in 
paediatric patients are the size of the patches and catheters 
and, in patients with non-sustained or haemodynamically 
unstable arrhythmias, the time needed to acquire the map. 
Cryoablation
Cryoenergy has been shown to be a safe and effective alter-
native to RFCA for the ablation of tachycardia substrates in 
adult patients.(18-20) Although modifications to the transcatheter 
delivery systems have made the use of cryoablation possible 
in paediatric patients, catheter size remains a problem in the 
smallest of patients.(21) Possible advantages of cryoablation 
compared to RFCA in particular include safety in ablation near 
the AV node by using cryomapping. Cryomapping allows for 
the evaluation of the acute, reversible effects of cryo before 
applying a permanent lesion. Another advantage is cryo-
adherence as the formation of an ice ball at the tip of the 
catheter permits adhesion of the catheter to the endocardium, 
thus increasing stability and reducing the need for fluoroscopy 
during ablation. There is also a decreased risk of thrombo-
embolism and coronary artery stenosis after cryoablation 
compared to RFCA.(22) Patient discomfort is also less during 
cryoapplication.(23)
The acute success rate for cryoablation for AVNRT is 
comparable with RFCA (94% vs. 96%), but the recurrence rate 
is higher (12% vs. 6%).(24) The total success rate for APs is lower 
than RFCA (75% vs. 92%) but it is comparable for midseptal 
and anteroseptal APs (i.e. close to the His bundle). Thus 
cryoablation should probably be used specifically to ablate 
substrates close to the AV junction.
CONCLUSION
Radiofrequency catheter ablation provides a safe and effective 
treatment option for selected paediatric patients, including 
infants, with outcomes in experienced paediatric centres similar 
to those seen in the adult population. It may be considered as 
first line therapy in selected situations, including in infants with 
refractory and/or life threatening arrhythmias. An electro-
physiololgy study should be considered in the patient with 
asymptomatic preexcitation, aged 5 years and older, due to the 
risk of sudden cardiac death.
Conflict of interest: none declared.
D
TABLE II: Indications for radiofrequency catheter ablation in 
paediatric patients with idiopathic ventricular arrhythmias.
Class I: There is consistent agreement and/or supportive data that catheter ablation is 
likely to be medically beneficial or helpful for the patient.
Class II: There is a divergence of opinion regarding the benefit or medical necessity of 
catheter ablation. II A: The majority of opinions/data are in favour of the procedure. 
II B: There is clear divergence of opinion regarding the need for the procedure.
Class III: There is agreement that catheter ablation is not medically indicated and/or 
the risk of the procedure may be greater than benefit for the patient.
VT = ventricular tachycardia.
Adapted from: Crosson, et al. PACES/HRS Expert consensus statement on the 
evaluation and management of ventricular arrhytmias in the child with a structurally 






Ventricular dysfunction or haemodynamic compromise 
presumed to be due to ventricular ectopy or VT; either as 
primary therapy or with failed medical therapy.
Intrafasicular verapamil-sensitive reentrant VT; either as primary 
therapy or if not controlled by calcium-channel blockers.
Symptomatic children with presumed idiopathic outfl ow 
tract VT.
Symptomatic children with symptoms due to frequent 
ventricular ectopy or accelerated idioventricular rhythm.
In patients with polymorphic VT where one morphology 
dominates or when a suspected trigger can be targeted.
Infants and toddlers, except in the case of haemodynamically 
signifi cant VT that cannot be adequately controlled medically.
Asymptomatic ventricular ectopy or VT that is not causing 
ventricular dysfunction.
Ventricular arrhythmias due to transient reversible causes, such 
as myocarditis or drug toxicity.
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